Related Experiment Video

Updated: Aug 23, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine

Elvire Pons-Tostivint1, Jaafar Bennouna2

  • 1Medical Oncology, Centre Hospitalier Universitaire Nantes, Nantes University, F-44000 Nantes, France.

Current Oncology (Toronto, Ont.)
|October 27, 2022
PubMed

Insights

Molecular diagnostics have revolutionized advanced non-small-cell lung cancer (NSCLC) care, enabling personalized treatment strategies. This shift focuses on tailoring therapies based on individual patient molecular profiles for better outcomes.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genomics

Background:

  • Advanced non-small-cell lung cancer (NSCLC) management has been significantly impacted by recent molecular diagnostic advancements.
  • Personalized medicine approaches are becoming standard in NSCLC care.

Discussion:

  • The integration of molecular diagnostics allows for precise patient stratification.
  • Targeted therapies are increasingly guided by specific genetic mutations identified in NSCLC tumors.

Key Insights:

  • Molecular profiling is crucial for identifying actionable mutations in NSCLC.
  • Tailored therapeutic strategies improve patient outcomes and treatment efficacy.

Outlook:

  • Continued research in molecular diagnostics will further refine NSCLC treatment paradigms.
  • Future directions include liquid biopsies and comprehensive genomic profiling for broader application.

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.7K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K